Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hi...( HONOLULU Sept. 17 /- In a new ana...),Health

HONOLULU, Sept. 17 /PRNewswire-FirstCall/ -- In a new analysis reported at the American Society for Bone and Mineral Research (ASBMR) 29th Annual Meeting, risedronate 5 mg decreased clinical fracture risk by 50% over three years relative to placebo in a group of postmenopausal women with osteoporosis who had suffered a previous hip fracture. This retrospective analysis of the risedronate HIP trial(1) evaluated the combined incidence of vertebral and nonvertebral clinical fractures among this high risk group of patients.

"As physicians we want assurance that a therapy is effective at treating varying severities of disease," said Michael McClung, M.D., Founding Director of the Oregon Osteoporosis Center in Portland and a primary investigator of the study. "In this analysis risedronate effectively reduced fracture risk among patients with severe osteoporosis."

According to the National Osteoporosis Foundation, a history of prior fracture is an important risk factor for future fracture. After a postmenopausal woman suffers a hip fracture, her risk approximately doubles for sustaining another fracture.

"These at-risk patients need to be identified and considered for therapy that can help prevent another fracture from occurring," said Dr. McClung.

About the Analysis

In the HIP trial(1), there were 339 postmenopausal women between ages 70-79 years with low bone mineral density (BMD) and a history of at least one hip fracture prior to the study. These patients were treated with either placebo (PLC) or risedronate (RIS) 2.5 mg or 5 mg daily. Over the 3 year period, the clinical fracture incidences were 28.4%, 14.9% and 13% for the PLC, RIS 2.5 mg and RIS 5 mg groups, respectively. This corresponds to a 50% reduction in clinical fracture risk relative to placebo for both the 2.5 mg and 5 mg treatment groups (p=0.031 and p=0.048, respectively).

The incidence of osteoporosis-related clinical fracture, defined by the occurrence of radio
'/>"/>